Dr. David G. Bostwick Returns as Chief Executive Officer of Bostwick Laboratories
August 2016 - Bostwick Laboratories is pleased to announce that Bostwick Founder and Former Chief Executive Officer Dr. David G. Bostwick, MD, MBA, has returned to the role of Chief Executive Officer,...
Bostwick Laboratories is now in-network with UnitedHealthcare
Effective October 1st, 2015, Bostwick Laboratories is now in-network with UnitedHealthcare.
This agreement brings Bostwick Laboratories’ CAP-accredited anatomic pathology labo...
Bostwick Laboratories to use Sienna reagent in world-first telomerase stain for bladder cancer launched today
January 9, 2015 - Bostwick Laboratories, the USA’s leading uropathology laboratory has announced a commercial agreement with the Australian group, Sienna Cancer Diagnostics (Melbourne),...
MDxHealth and Bostwick Laboratories Announce Marketing Agreement for ConfirmMDx™ for Prostate Cancer
Irvine, CA, Uniondale, NY and Liege, Belgium – 8:00 AM CET, July 29, 2013 – MDxHealth SA (NYSE Euronext: MDXH) and Bostwick Laboratories, Inc. today announced that they have e...
Bostwick Laboratories Hires Vice President of Sales
Bostwick Laboratories announces the hiring of Robert Phillips as Vice President of Sales. Robert will lead the sales efforts for Bostwick Laboratories across all divisions and products.
Bostwick to Attend AUA's 2013 Annual Meeting
Bostwick Laboratories will be exhibiting at the 2013 American Urological Association Annual Meeting, held on May 4-8 in San Diego, CA.
Dr. David G. Bostwick to Present Prostavysion and BladderVysion at AUA's 2012 Annual Meeting
Dr. David G. Bostwick, CMO of Bostwick Laboratories, is slated to present on ProstaVysion and BladderVy...
Healthcare Finance Group, LLC Underwrites a $43.0 Million Financing Facility for Bostwick Laboratories, Inc.
Glen Allen, VA - July 7, 2011 - Healthcare Finance Group, LLC (“HFG”) today announced that it has underwritten a $43 million Senior Secured Credi...
New Personalized Genetic Test- Prostavysion™ - Helps Prostate Cancer Patients Make Best Treatment Decisions
Test Defines the Aggressiveness of Prostate Cancer
Richmond, VA - May 11, 2011 - Treatment of prostate cancer is often ...
Bostwick Laboratories Chooses XIFIN for Revenue Cycle Management
Fast-Growing Anatomic Pathology Lab Leverages Advanced Technology Claims Management, Reporting and Analytics System
San Diego, C...